3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Hepatocellular
115
Cholangiocarcinoma
24
Carcinoma, Renal Cell
20
Liver Neoplasms
12
Stomach Neoplasms
10
Biliary Tract Neoplasms
10
Thyroid Neoplasms
8
Endometrial Neoplasms
8
Breast Neoplasms
8
Neoplasms
7
Recurrence
6
Neuroendocrine Tumors
5
Neoplasm Metastasis
5
Melanoma
5
Uterine Cervical Neoplasms
4
Thyroid Carcinoma, Anaplastic
4
Thyroid Cancer, Papillary
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Liver Diseases
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Carcinoma, Adenoid Cystic
3
Brain Neoplasms
3
Advanced Biliary Tract Cancer
3
Adenocarcinoma, Follicular
3
Adenocarcinoma
3
Uveal Melanoma
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Interventions
lenvatinib
1
camrelizumab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Advanced Triple Negative Breast Cancer
×
lenvatinib
×
Clear all
NCT06849492
2025-02-27
SHIFT-001
Fudan University
Phase 2
Not yet recruiting
120 enrolled